Danske Bank A/S Neurocrine Biosciences Inc Transaction History

Danske Bank A/S

  • $1.95 Trillion
  • Q3 2025

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 19, 2025
BUY
$123.98 - $146.67 $5.38 Million - $6.37 Million
43,416 New
43,416 $6.09 Million
Q2 2025

Dec 18, 2025
BUY
$87.54 - $128.18 $102,334 - $149,842
1,169 Added 2.68%
44,716 $5.62 Million
Q1 2025

Dec 18, 2025
BUY
$107.22 - $153.29 $14,045 - $20,080
131 Added 0.3%
43,547 $4.82 Million

Others Institutions Holding NBIX

# of Institutions
724
Shares Held
102M
Call Options Held
230K
Put Options Held
477K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Danske Bank A/S Portfolio

Follow Danske Bank A/S and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Danske Bank A/S, based on Form 13F filings with the SEC.

News

Stay updated on Danske Bank A/S with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email